NRAS and melanoma: In parallel to “genetic” resistance to MAPKi, due to the acquisition of genetic mutations, affecting NRAS or MEK (Nazarian et al, 2010; Van Allen et al, 2014), the present study emphasizes melanoma cell plasticity as a potent driver of “phenotypic” resistance (Roesch, 2015).